Medication info
Mirtel Plus Tablets 40/12.5 Milligrams

Mirtel Plus Tablets 40/12.5 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›40mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Samchundang Pharm. Co., Ltd.
Appearance
White or nearly white, biconvex round tablets
Packaging
30 tablets (10 tablets/PTP x 3)
Approval status
Active

MFDS item code 201701098 · Approved 2017.02.28 · Insurance code 651204980

Summary

Main use
Treatment of essential hypertension
Who takes it
Adults · Children
Adult dose
Adults For patients whose blood pressure is not adequately controlled with telmisartan monotherapy, take this medicine once daily with a drink, with or without food. Before switching to this medicine, which contains fixed doses of each component, it is recommended that the doses of the individual components be adjusted separately according to the patient's needs. When clinically appropriate, a direct switch from monotherapy to this medicine may also be considered. - The telmisartan/hydrochlorothiazide combination 40/12.5mg may be administered to patients whose blood pressure is not adequately controlled with telmisartan 40mg. - The telmisartan/hydrochlorothiazide combination 80/12.5mg may be administered to patients whose blood pressure is not adequately controlled with telmisartan 80mg. - The telmisartan/hydrochlorothiazide combination 80/25mg may be administered to patients whose blood pressure is not adequately controlled with telmisartan 80mg plus hydrochlorothiazide 12.5mg as separate products or with the combination product. Sodium or volume depletion should be corrected before starting this medicine. Patients with renal impairment No dose adjustment is necessary in patients with mild to moderate renal impairment. Do not administer this medicine to patients with severe renal impairment (creatinine clearance<30mL/min). Periodic monitoring of renal function is recommended. Patients with hepatic impairment Use this medicine with caution in patients with mild to moderate hepatic impairment. Do not administer more than 40/12.5mg of this medicine once daily. Do not administer this medicine to patients with severe hepatic impairment (see Precautions for Use 2.). Thiazide diuretics should be used with caution in patients with impaired liver function. Older adults No dose adjustment is necessary.
Child dose
The safety and efficacy of this medicine have not been established in children under 18 years of age.

Ingredients

Manufacturer
Samchundang Pharm. Co., Ltd.

Efficacy & effects

Treatment of essential hypertension

  • Primary hypertension
View approved original text

This medication is used in patients with primary hypertension where blood pressure control is difficult with telmisartan alone. It effectively controls blood pressure and helps prevent cardiovascular complications.

How to take

Adult dose

Adults For patients whose blood pressure is not adequately controlled with telmisartan monotherapy, take this medicine once daily with a drink, with or without food. Before switching to this medicine, which contains fixed doses of each component, it is recommended that the doses of the individual components be adjusted separately according to the patient's needs. When clinically appropriate, a direct switch from monotherapy to this medicine may also be considered. - The telmisartan/hydrochlorothiazide combination 40/12.5mg may be administered to patients whose blood pressure is not adequately controlled with telmisartan 40mg. - The telmisartan/hydrochlorothiazide combination 80/12.5mg may be administered to patients whose blood pressure is not adequately controlled with telmisartan 80mg. - The telmisartan/hydrochlorothiazide combination 80/25mg may be administered to patients whose blood pressure is not adequately controlled with telmisartan 80mg plus hydrochlorothiazide 12.5mg as separate products or with the combination product. Sodium or volume depletion should be corrected before starting this medicine. Patients with renal impairment No dose adjustment is necessary in patients with mild to moderate renal impairment. Do not administer this medicine to patients with severe renal impairment (creatinine clearance<30mL/min). Periodic monitoring of renal function is recommended. Patients with hepatic impairment Use this medicine with caution in patients with mild to moderate hepatic impairment. Do not administer more than 40/12.5mg of this medicine once daily. Do not administer this medicine to patients with severe hepatic impairment (see Precautions for Use 2.). Thiazide diuretics should be used with caution in patients with impaired liver function. Older adults No dose adjustment is necessary.

Child dose

The safety and efficacy of this medicine have not been established in children under 18 years of age.

Precautions

This medication may cause serious harm to the fetus if used during pregnancy; therefore, women who are pregnant or planning to become pregnant should not take it. Patients with allergies to any of the components of this medication or with certain liver or kidney diseases should not use it. Caution is required when used in the elderly, patients with high potassium levels, or those with liver function problems, and in patients with heart disease. If new skin lesions appear while taking this medication, consult a doctor immediately and avoid sun exposure. This medication lowers blood pressure, which may cause dizziness or fainting, thus caution is advised while driving or operating machinery. This medication may affect kidney function, so patients with kidney disease should regularly check kidney function and electrolyte levels through blood tests. This medication may interact with other drugs, so inform your healthcare provider of any medications you are currently taking. Overdose may result in hypotension, electrolyte imbalance, or dehydration, requiring immediate medical attention. The safety and efficacy of this medication are not established in children and adolescents under the age of 18, so it is not recommended.

Side effects

  • Hypotension
  • decreased cranial formation in neonates
  • anuria
  • renal failure
  • death
  • oligohydramnios
  • fetal limb contracture
  • craniofacial deformities
  • pulmonary hypoplasia
  • prematurity
Show 138 more
  • intrauterine growth restriction
  • patent ductus arteriosus
  • bronchitis
  • pharyngitis
  • sinusitis
  • hypokalemia
  • hyperuricemia
  • hyponatremia
  • anxiety
  • depression
  • insomnia
  • sleep disorders
  • dizziness
  • syncope
  • paresthesia
  • visual impairment
  • blurred vision
  • vertigo
  • tachycardia
  • arrhythmia
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • respiratory distress
  • pneumonia
  • pulmonary edema
  • diarrhea
  • dry mouth
  • abdominal distension
  • abdominal pain
  • constipation
  • dyspepsia
  • vomiting
  • gastritis
  • abnormal liver function
  • liver disorders
  • vascular edema
  • erythema
  • pruritus
  • rash
  • hyperhidrosis
  • urticaria
  • back pain
  • muscle cramps
  • myalgia
  • arthralgia
  • limb pain
  • systemic lupus erythematosus
  • erectile dysfunction
  • chest pain
  • influenza-like illness
  • pain
  • elevated blood uric acid
  • elevated blood creatinine
  • increased blood creatine phosphokinase
  • elevated liver enzymes
  • upper respiratory tract infection
  • urinary tract infection
  • cystitis
  • sepsis
  • anemia
  • eosinophilia
  • thrombocytopenia
  • anaphylactic reaction
  • hyperkalemia
  • hypoglycemia
  • drowsiness
  • bradycardia
  • cough
  • interstitial lung disease
  • dry mouth
  • abdominal discomfort
  • taste disturbances
  • eczema
  • drug rash
  • toxic epidermal necrolysis
  • bone pain
  • renal dysfunction
  • asthenia
  • decreased hemoglobin
  • sialadenitis
  • non-melanoma skin cancer
  • thrombocytopenic purpura
  • hemolytic anemia
  • bone marrow failure
  • leukopenia
  • agranulocytosis
  • hypersensitivity
  • aplastic anemia
  • hyperlipidemia
  • decreased appetite
  • hypomagnesemia
  • hyperglycemia
  • hypercalcemia
  • hypochloremic metabolic alkalosis
  • yellow vision
  • acute myopia
  • angle-closure glaucoma
  • choroidal effusion
  • necrotizing vasculitis
  • acute respiratory distress syndrome
  • nausea
  • pancreatitis
  • jaundice
  • cholestasis
  • photosensitivity reaction
  • toxic epidermal necrolysis
  • systemic lupus erythematosus
  • acute renal failure
  • diabetes
  • renal dysfunction
  • asthenia
  • fever
  • dizziness
  • pruritus
  • myalgia
  • headache
  • floaters
  • nausea
  • gastrointestinal bleeding
  • esophagitis
  • fatigue
  • weight loss
  • proteinuria
  • lip and hand tremors
  • sensory hyperreactivity
  • visual impairment
  • hypotension
  • tachycardia
  • bradycardia
  • orthostatic hypotension
  • dyspnea
  • cough
  • diarrhea
  • abdominal distension
  • abdominal pain
  • dyspepsia
  • vomiting

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture, and it is best stored at room temperature between 1°C and 30°C. By storing it this way, the effectiveness of the medication can be maintained for a longer period.

Appearance and packaging

Appearance

White or nearly white, biconvex round tablets

Package unit

30 tablets (10 tablets/PTP x 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.